ATS Resume Optimization for Cell & Gene Therapy (CGT) Manufacturing Specialists

This title is distinct from the site's built Process/Manufacturing Engineer (Pharma) page: Process Engineer covers the broader facility-design and production-optimization role across all pharma modalities — small molecule, biologics, sterile injectables, and ATMPs — while CGT Manufacturing Specialist is a narrower, hands-on operational specialization in viral-vector production, cell processing and apheresis, cryopreservation, and chain-of-identity/chain-of-custody logistics, the same 'tier below a broader title' pattern as GMP Auditor sitting under QA/QC Specialist. It also carries the strongest 'why now' hook in the vertical: Barrington James's directly-fetched 2026 Outlook report projects the CGT market will reach $54.4bn by 2030, cites 45 FDA-approved CGT products and 700+ active US clinical assets as of 2025, and names MSAT/process development, quality, and cold-chain/logistics among the sector's highest-demand 2026 hiring functions, stating plainly that 'manufacturing readiness is now a primary determinant of funding, valuation, and hiring.' Ireland's evidence is unusually specific here too: NIBRT's dedicated CGT Forum and a new €21m ATMP training facility (IDA Ireland and Irish-government funded) sit alongside dedicated MSc programs at Atlantic Technological University and UCC. We rewrite your resume and LinkedIn profile so your viral-vector, cell-processing, and chain-of-custody experience match exactly what CGT recruiters filter on — distinct from generic process-engineering language.